Business Description
Voyager Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92915B1061
Total Employee Number:
141Description
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.09 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.28 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -1.07 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -13.6 | |||||
3-Year EBITDA Growth Rate | -23.2 | |||||
3-Year EPS without NRI Growth Rate | -19 | |||||
3-Year FCF Growth Rate | -80.5 | |||||
3-Year Book Growth Rate | 29.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.19 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 30.65 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.91 | |||||
9-Day RSI | 44.23 | |||||
14-Day RSI | 45.86 | |||||
3-1 Month Momentum % | -5.15 | |||||
6-1 Month Momentum % | -7.88 | |||||
12-1 Month Momentum % | 41.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.42 | |||||
Quick Ratio | 8.42 | |||||
Cash Ratio | 8.11 | |||||
Days Sales Outstanding | 19.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.2 | |||||
Shareholder Yield % | 1.88 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -349.16 | |||||
Net Margin % | -319.61 | |||||
EBITDA Margin % | -338.26 | |||||
FCF Margin % | -357.69 | |||||
OCF Margin % | -352.3 | |||||
ROE % | -52.71 | |||||
ROA % | -40.63 | |||||
ROIC % | -78.87 | |||||
3-Year ROIIC % | 241.74 | |||||
ROC (Joel Greenblatt) % | -150.43 | |||||
ROCE % | -50.02 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.76 | |||||
PB Ratio | 1.24 | |||||
Price-to-Tangible-Book | 1.24 | |||||
EV-to-EBIT | -0.85 | |||||
EV-to-Forward-EBIT | 40.62 | |||||
EV-to-EBITDA | -0.88 | |||||
EV-to-Forward-EBITDA | -0.93 | |||||
EV-to-Revenue | 2.98 | |||||
EV-to-Forward-Revenue | 2.62 | |||||
EV-to-FCF | -0.84 | |||||
Price-to-GF-Value | 2.12 | |||||
Price-to-Median-PS-Value | 0.89 | |||||
| Price-to-Net-Current-Asset-Value | 2.12 | |||||
| Price-to-Net-Cash | 2.25 | |||||
Earnings Yield (Greenblatt) % | -117.65 | |||||
FCF Yield % | -60.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Voyager Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 31.235 | ||
| EPS (TTM) (€) | -1.702 | ||
| Beta | 0.3111 | ||
| 3-Year Sharpe Ratio | -0.42 | ||
| 3-Year Sortino Ratio | -0.61 | ||
| Volatility % | 50.12 | ||
| 14-Day RSI | 45.86 | ||
| 14-Day ATR (€) | 0.097085 | ||
| 20-Day SMA (€) | 2.9904 | ||
| 12-1 Month Momentum % | 41.17 | ||
| 52-Week Range (€) | 2.286 - 4.872 | ||
| Shares Outstanding (Mil) | 60.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Voyager Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Voyager Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 135 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 39 days | ||
| H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference | 2026-06-15 07:00 | 2.85 (+0.00%) | ||
| General meeting for 2026 | 2026-06-09 09:00 | 2.75 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.18 (+0.00%) | ||
| Guidance call for 2026 | 2026-03-18 12:30 | 3.56 (+0.00%) | ||
| Guidance call for 2026 | 2026-03-10 10:40 | 3.26 (+0.00%) | ||
| Annual report for 2025 | 2026-03-09 | 3.23 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 3.23 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 13:10 | 3.40 (+0.00%) |
Show
Entries
Voyager Therapeutics Inc Frequently Asked Questions
What is Voyager Therapeutics Inc(FRA:VT6)'s stock price today?
The current price of FRA:VT6 is €2.94. The 52 week high of FRA:VT6 is €4.87 and 52 week low is €2.29.
When is next earnings date of Voyager Therapeutics Inc(FRA:VT6)?
The next earnings date of Voyager Therapeutics Inc(FRA:VT6) is 2026-08-06 Est..
Does Voyager Therapeutics Inc(FRA:VT6) pay dividends? If so, how much?
Voyager Therapeutics Inc(FRA:VT6) does not pay dividend.
Press Release
Articles on Voyager Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers